Loading clinical trials...
Loading clinical trials...
A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Conditions
Interventions
GRN163L in combination with trastuzumab
Locations
1
United States
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
Start Date
January 1, 2011
Primary Completion Date
August 1, 2012
Completion Date
October 1, 2015
Last Updated
October 27, 2015
NCT07191730
NCT06797635
NCT06312176
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Indiana University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions